JP2022553173A - 代謝症候群の治療管理のためのクルクミノイド組成物 - Google Patents

代謝症候群の治療管理のためのクルクミノイド組成物 Download PDF

Info

Publication number
JP2022553173A
JP2022553173A JP2022522603A JP2022522603A JP2022553173A JP 2022553173 A JP2022553173 A JP 2022553173A JP 2022522603 A JP2022522603 A JP 2022522603A JP 2022522603 A JP2022522603 A JP 2022522603A JP 2022553173 A JP2022553173 A JP 2022553173A
Authority
JP
Japan
Prior art keywords
demethoxycurcumin
mammal
weight
octahydrocurcuminoid
metabolic syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022522603A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021076766A5 (https=
JP2022553173A5 (https=
Inventor
ムハンメド マジード
カリヤナム ナガブシャナム
ラクシュミ ムンドクル
ラジェンドラン ラマヌジャム
Original Assignee
サミ－サビンサ グループ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サミ－サビンサ グループ リミテッド filed Critical サミ－サビンサ グループ リミテッド
Publication of JP2022553173A publication Critical patent/JP2022553173A/ja
Publication of JPWO2021076766A5 publication Critical patent/JPWO2021076766A5/ja
Publication of JP2022553173A5 publication Critical patent/JP2022553173A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022522603A 2019-10-15 2020-10-15 代謝症候群の治療管理のためのクルクミノイド組成物 Pending JP2022553173A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962915068P 2019-10-15 2019-10-15
US62/915,068 2019-10-15
PCT/US2020/055796 WO2021076766A1 (en) 2019-10-15 2020-10-15 Curcuminoid composition for therapeutic management of metabolic syndrome

Publications (3)

Publication Number Publication Date
JP2022553173A true JP2022553173A (ja) 2022-12-22
JPWO2021076766A5 JPWO2021076766A5 (https=) 2023-09-22
JP2022553173A5 JP2022553173A5 (https=) 2023-09-22

Family

ID=75382361

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022522603A Pending JP2022553173A (ja) 2019-10-15 2020-10-15 代謝症候群の治療管理のためのクルクミノイド組成物
JP2022522601A Pending JP2022551967A (ja) 2019-10-15 2020-10-15 クルクミノイド組成物および肺線維症の管理におけるその治療能力

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022522601A Pending JP2022551967A (ja) 2019-10-15 2020-10-15 クルクミノイド組成物および肺線維症の管理におけるその治療能力

Country Status (6)

Country Link
US (2) US11707438B2 (https=)
EP (2) EP4045478B1 (https=)
JP (2) JP2022553173A (https=)
CN (2) CN114746102A (https=)
CA (2) CA3153877C (https=)
WO (2) WO2021076766A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230255969A1 (en) * 2020-07-23 2023-08-17 National University Of Singapore Targeting immune pathologies induced by highly pathogenic coronaviruses
JP2023554640A (ja) * 2020-12-17 2023-12-28 サミ－サビンサ グループ リミテッド 慢性炎症状態において終末糖化産物受容体（ｒａｇｅ）を標的とするための組成物
WO2022203674A1 (en) * 2021-03-25 2022-09-29 Majeed, Muhammed Compositions and methods for managing nephropathy
BR112023022756A2 (pt) * 2021-04-30 2024-01-02 Sami Sabinsa Group Ltd Composições para gerenciamento de síndrome de ovário policístico

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003002827A (ja) * 2001-06-20 2003-01-08 Kyowa Hakko Kogyo Co Ltd 血中中性脂肪の増加の予防又は改善剤
CN101732292A (zh) * 2010-01-25 2010-06-16 四川省中医药科学院 四氢姜黄素的新用途
US20170258743A1 (en) * 2014-12-15 2017-09-14 Aurea Biolabs Private Limited A Process for Preparation of Bioavailable White Curcumin - A Unique Blend of Hydrogenated Curcuminoids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0249747A (ja) 1988-08-12 1990-02-20 Kobe Steel Ltd 抗酸化剤
US6653327B2 (en) * 1999-04-09 2003-11-25 Sabinsa Corporation Cross-regulin composition of tumeric-derived tetrahydrocurcuminoids for skin lightening and protection against UVB rays
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US20060263309A1 (en) * 2005-05-17 2006-11-23 Bissett Donald L Regulation of mammalian keratinous tissue using personal care compositions comprising tetrahydrocurcumin
US20080031980A1 (en) * 2006-08-02 2008-02-07 Al Rodriguez Curcumin-containing composition, methods of making, and methods of using
US20080058426A1 (en) * 2006-08-29 2008-03-06 Muhammed Majeed Composition and method for treating psoriasis
CN101255119B (zh) * 2008-01-07 2014-05-21 沈阳药科大学 四氢姜黄素衍生物及盐类
JP2012521412A (ja) * 2009-03-23 2012-09-13 ライラ ファーマシューティカルズ ピーブイティ．エルティディ． 鼻のアレルギー疾患において適用するためのクルクミノイドおよびその代謝物
CN102526004A (zh) * 2010-01-25 2012-07-04 四川省中医药科学院 四氢姜黄素的新用途
WO2011124573A1 (en) * 2010-04-09 2011-10-13 Unilever Plc Oral care compositions
CN102078312A (zh) * 2010-12-24 2011-06-01 中国药科大学 一种姜黄素类化合物干粉吸入剂及其制备方法和用途
US9170257B2 (en) * 2012-06-14 2015-10-27 Signpath Pharma Inc. Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
US20150283093A1 (en) * 2014-04-07 2015-10-08 Muhammed Majeed Nanoencapsulation of curcuminoid metabolites - process, composition and applications thereof
US9642886B2 (en) * 2014-08-25 2017-05-09 Srm University Plant based formulation for the prevention and management of metabolic syndrome by its adiponectin enhancing property
KR102876481B1 (ko) * 2017-03-17 2025-10-27 케랄라 아유르베다 리미티드 (인디아) 약초 조성물
CN108771664B (zh) * 2018-06-05 2020-09-08 中山大学 四氢姜黄素在改善过敏性哮喘的应用
CN109833457A (zh) * 2019-02-28 2019-06-04 孟凤仙 虎杖及姜黄及其活性物在治疗间质性肺病中的应用
CN109674742A (zh) * 2019-03-07 2019-04-26 康赋葆(深圳)生物医药科技有限公司 一种姜黄素类亲水凝胶骨架缓释组合物、制备方法及其在抗癌领域的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003002827A (ja) * 2001-06-20 2003-01-08 Kyowa Hakko Kogyo Co Ltd 血中中性脂肪の増加の予防又は改善剤
CN101732292A (zh) * 2010-01-25 2010-06-16 四川省中医药科学院 四氢姜黄素的新用途
US20170258743A1 (en) * 2014-12-15 2017-09-14 Aurea Biolabs Private Limited A Process for Preparation of Bioavailable White Curcumin - A Unique Blend of Hydrogenated Curcuminoids

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J AGRIC FOOD CHEM, vol. 66:12685-12695, JPN6024034396, 2018, ISSN: 0005404164 *
RENAL FAILURE, vol. 29:881-889, JPN6024034397, 2007, ISSN: 0005404165 *
RES J CHEM SCI, vol. 5(4):33-36, JPN5023000717, 2015, ISSN: 0005404163 *

Also Published As

Publication number Publication date
EP4045478B1 (en) 2026-01-28
US11491119B2 (en) 2022-11-08
CA3153877C (en) 2024-04-02
CN114746102A (zh) 2022-07-12
US20210106544A1 (en) 2021-04-15
EP4045071A1 (en) 2022-08-24
EP4045478A4 (en) 2024-01-10
CA3153879A1 (en) 2021-04-22
CA3153877A1 (en) 2021-04-22
EP4045071A4 (en) 2023-11-29
CN114728876A (zh) 2022-07-08
EP4045071B1 (en) 2026-02-25
EP4045478A1 (en) 2022-08-24
WO2021076766A1 (en) 2021-04-22
WO2021076771A1 (en) 2021-04-22
US20210106543A1 (en) 2021-04-15
JP2022551967A (ja) 2022-12-14
US11707438B2 (en) 2023-07-25

Similar Documents

Publication Publication Date Title
EP4045071B1 (en) Curcuminoid composition for therapeutic management of metabolic syndrome
Ulla et al. Supplementation of Syzygium cumini seed powder prevented obesity, glucose intolerance, hyperlipidemia and oxidative stress in high carbohydrate high fat diet induced obese rats
Reiter et al. Anti-inflammatory properties of α-and γ-tocopherol
Seiva et al. Quercetin ameliorates glucose and lipid metabolism and improves antioxidant status in postnatally monosodium glutamate-induced metabolic alterations
Bialonska et al. Urolithins, intestinal microbial metabolites of pomegranate ellagitannins, exhibit potent antioxidant activity in a cell-based assay
Izadi et al. Longevity and anti-aging effects of curcumin supplementation
He et al. The anti-obesity effects of polyphenols: a comprehensive review of molecular mechanisms and signal pathways in regulating adipocytes
Park et al. Olive leaf down-regulates the oxidative stress and immune dysregulation in streptozotocin-induced diabetic mice
Afzal et al. Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats
Ravikumar et al. Effect of Tridax procumbens on liver antioxidant defense system during lipopolysaccharide-induced hepatitis in D-galactosamine sensitised rats
Al-Numair Hypocholesteremic and antioxidant effects of garlic (Allium sativum L.) extract in rats fed high cholesterol diet
CN107949394A (zh) 包含黑豆叶提取物及从其分离的黄酮醇苷作为活性成分的用于预防或治疗代谢综合征或用于抗氧化的组合物
CA2847543C (en) Annatto extract compositions, including geranyl geraniols and methods of use
US9439936B2 (en) Inhibitor of inflammatory conditions
CN105744942A (zh) 五层龙组合物，通过其施用的治疗方法，及其制备方法
Zhao et al. Anthocyanins in vascular health and disease: mechanisms of action and therapeutic potential
Silva et al. Effect of Curcuma longa L. and curcumin on diabetes and it’s complications: A review
US20070237845A1 (en) Methods and materials for reducing or eliminating risk factors associated with syndrome x
Lin et al. Analgesic and anti-inflammatory activities of Torenia concolor Lindley var. formosana Yamazaki and betulin in mice
CN1745747B (zh) 原花青素在制备治疗结肠炎药物的新用途
Kshirsagar et al. Geranium oil ameliorates endothelial dysfunction in high fat high sucrose diet induced metabolic complications in rats
Veeramani et al. Effects of Melothria maderaspatana leaf extract on antioxidant status in sham-operated and uninephrectomized DOCA-salt hypertensive rats
Orallo Biological effects of cis-versus trans-resveratrol
US20230381117A1 (en) Anti-obesity potential of bisdemethoxycurcumin compositions
Barre et al. The polypharmacy reduction potential of cinnamic acids and some related compounds in pre-and post-onset management of type 2 diabetes mellitus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250303